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ABSTRACT 
Background: Intrathecal drug delivery (ITDD) systems are one of a limited number of management 
options for chronic non-cancer pain, cancer pain and spasticity. Concerns over their effectiveness 
and high initial costs led NHS England to decommission ITDD for patients with chronic non-cancer 
pain. However, the extent to which this decision is in line with existing economic evidence is unclear. 
The aim of this systematic review is to identify and review the existing evidence on the cost-
effectiveness of ITDD for chronic non-cancer pain.  
Methods: Full and partial economic evaluations on ITDD were identified through systematic searches 
in MEDLINE, EMBASE, Web of Science and the National Health Service Centre for Reviews and 
Dissemination databases. Database searches were complemented by hand searching of reference 
lists of relevant studies and searches of grey literature. Study selection was carried out by two 
assessors, independently. Study quality assessment was performed to inform critical appraisal of 
health economics studies. Data were extracted using a data extraction form developed for this 
study. 
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Results: 4464 unique studies were identified, of which seven met the inclusion criteria. With the 
exception of one study, the studies found ITDD to be either cost-saving or cost-effective compared 
to conventional medical management. ITDD becomes cost-ineffective in one further study following 
price year adjustment to 2016. 
Conclusions: Study findings show ITDD as not cost-effective only in extremely conservative scenarios. 
There is limited evidence on the effectiveness of ITDD in non-cancer pain; however, the available 
economic evidence controverts arguments to refute the treatment on economic grounds. 
 
Keywords: chronic pain, cost-effectiveness, economic evaluations, intrathecal drug delivery 
 
INTRODUCTION 
Estimates of the prevalence of chronic pain range between 13% to 51%.1-3 The variation across 
studies is mainly due to the employed definition of chronic pain and the populations studied. 
Regardless, the prevalence of chronic pain is higher than other common chronic conditions such as 
diabetes mellitus (Type 1 or Type 2), which has a considerably lower prevalence of 7% among men 
and 4.9% among women.4 Chronic pain presents a significant health burden associated with 
significant reductions in health-related quality of life. The National Pain Audit 2012 observed that 
the mean EuroQol index score in people suffering from chronic pain was 0.4, which is lower than 
that reported by people with progressive neurological disorders such as Parkinson’s disease (0.432).5 
Furthermore, persistent pain conditions such as neck pain, migraine, arthritis and low back pain 
cause more global disability than any other condition.6 
The economic burden of chronic pain is equally significant. The UK economy incurs about £12.3 
billion per year for managing back pain alone and costs associated with pain are estimated to be 
much higher.7 Chronic pain sufferers are seven times more likely to quit their jobs due to ill health 
than the general population, and chronic pain remains the second most common reason for claiming 
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incapacity benefit.7 More concretely, pain prevents 40% of people with chronic pain from working 
and causes an additional 12% to have reduced working hours.5 
Pain management strategies explored first include those options with the lowest risk of 
complications and least invasiveness. Treatment plans with higher risks are gradually introduced as 
the pain becomes refractory to previous options.8 
Spinal cord stimulation (SCS) and intrathecal drug delivery (ITDD) have been seen as ‘last resort’ 
options and are typically made available to patients who have experienced prolonged periods of 
pain, sometimes as long as 40 years.9-11 ITDD is used for the management of cancer and non-cancer 
pain, and spasticity.12,13 There are different levels of evidence for the use of ITDD in these different 
conditions.14-16 NHS England currently commissions ITDD for the management of cancer pain 17 and 
spasticity 18 but not for pain of non-cancer origin as it was considered that there was insufficient 
evidence to support routine commissioning in this patient group.19 Although the limitations of the 
effectiveness data are undeniable (randomised controlled trials [RCTs] are not available), poor 
quality economic evaluation studies were used to inform the commissioning decision for chronic 
non-cancer pain. 
The overarching aim of this systematic review is therefore to investigate the cost-effectiveness of 
ITDD systems using opioids for the management of chronic non-cancer pain. To the authors best 
knowledge this is the first systematic review on the topic. 
Accordingly, this work sets out to:  
- Search bibliographic sources to identify relevant evidence on the cost-effectiveness of ITDD 
as compared to conventional medical management (CMM); 
- Appraise the quality of the identified studies, and highlight their strengths and limitations; 
- Use evidence reported in the studies to determine the cost-effectiveness of ITDD as 
compared to CMM; 
- Discuss the potential policy implications of the findings, especially in relation to future policy 
reviews of ITDD for chronic non-cancer pain. 
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METHODS AND ANALYSIS 
The systematic review was conducted according to a pre-specified protocol.20 Systematic review 
registration number: PROSPERO CRD42016035266. The systematic review follows the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines.21 
 
Search methods for identification of studies 
Systematic searches were conducted to identify relevant economic evaluations of ITDD for the 
management of chronic non-cancer pain. The searches were carried out using the following 
electronic databases: MEDLINE(R) In-Process & Other Non-Indexed Citations and MEDLINE(R) (Ovid), 
EMBASE (Ovid), Science Citation Index (Web of Science), Conference Proceedings Citation Index 
(Web of Science), the National Health Service (NHS) Centre for Reviews and Dissemination databases 
NHS Economic Evaluation Database (EED), Database of Abstracts of Reviews of Effects (DARE) and 
Health Technology Assessment (HTA) (all via Wiley). Grey literature was searched using OpenGrey, 
GreyNet, GreyLit. Searches in the electronic databases were complemented by hand searching of 
reference lists of relevant studies. 
Databases were initially searched from their inception to 15th February 2016 and updated up to 5th 
September 2017. Economic studies filters designed by the NHS EED 22 and Scottish Intercollegiate 
Guidelines Network (SIGN) 23 to locate economic evaluation studies were used and a comprehensive 
search strategy developed (Appendix 1). No language restriction was applied in the searches. 
Literature search results were uploaded to and managed using EndNote X7.0.1 software. 
 
Study selection 
The selection criteria described in Table 1 were applied to the citations identified from the literature 
search. Two reviewers screened titles and abstracts of all retrieved citations independently. Where 
compliance with the selection criteria was unclear from titles and abstracts, full texts were retrieved. 
Full papers for studies deemed potentially relevant were retrieved and selection criteria were 
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applied. Disagreement was resolved by discussion and consensus between the two reviewers. A 
third reviewer would have been involved if dissenting opinions were observed and consensus was 
not reached. 
 
Data extraction 
Two reviewers extracted relevant information using an extraction form developed specifically for the 
purposes of this study. A third reviewer assessed the extracted data to ensure accuracy. 
Disagreements were resolved by discussion. Information was extracted in relation to the following 
factors: (1) general information including study author, year, funding source, country, setting, study 
design; (2) recruitment details, sample size, demographic characteristics (age, gender) and baseline 
health data (diagnosis, co-morbidities); (3) interventions, effectiveness data, cost data; (4) type of 
economic evaluation, perspective, time horizon, measure of benefit; (5) quality assessment; (6) 
results; (7) analysis of uncertainty; (8) conclusions. The outcomes for which data was sought were 
selected taking into account the data necessary to conduct an economic evaluation. 
 
[Insert Table 1 here] 
 
Quality assessment 
Quality assessment of all included studies was performed using the Evers checklist (all economic 
evaluations)25 and the Philips et al. checklist for model-based economic studies 26 as recommended 
in the Cochrane Handbook for Systematic Reviews of Interventions.27 Two reviewers independently 
assessed the quality of the included studies. Any discrepancies were resolved by discussion and 
consensus between the two reviewers and if necessary consultation of a third reviewer. 
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Data synthesis and reporting 
The results section was organised based on the good practice recommendations for narrative 
summary of health economic studies as outlined in the Cochrane Handbook for Systematic 
Reviews.28 To facilitate the comparison of estimates reported in different studies, monetary values 
reported in all the identified studies were converted to UK pounds sterling (£) at 2016 price year. 
The year the study was published was assumed as the price year for those studies not reporting this 
information. Conversion of cost estimates were performed using the CCEMG – EPPI-Centre Cost 
Converter web-based tool v.1.5. The CCEMG – EPPI-Centre Cost Converter tool takes into 
consideration international exchange rates based on Purchasing Power Parities and gross domestic 
product deflator values as recommended in the economics evidence section of the Cochrane 
Handbook for Systematic Reviews.28 
 
RESULTS 
The search identified 4891 records from database searches and reference lists. After removal of 
duplicates (n = 427) and records not meeting the eligibility criteria (n = 4448), 16 full-text articles 
were retrieved and assessed for eligibility. Nine studies were excluded from the review following 
assessment of the full-text for various reasons as shown in Figure 1. One cost description study was 
excluded because the study population comprised patients with spasticity (14%), cancer pain (6%) 
and other chronic pain conditions but cost results were not presented separately for the different 
aetiologies.29 Another study that compared the costs of ITDD to external infusion pumps was 
excluded because 60% of the patients had cancer pain and the cost comparison was not presented 
for each patient group.30 Three of the nine studies were narrative reviews of other economic 
evaluations already included in this review, and were therefore excluded.31-33 Staats et al 34 did not 
report any cost data and the conference abstract by Sawyer and Blowey 35 presented no information 
on how the total cost estimate (£460,000 for all the patients in the study, equivalent to £24,000 per 
patient) was calculated. Both records were excluded. The last two studies were excluded because an 
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economic evaluation of ITDD therapy was not performed; either only the cost impact of dose 
escalation 36 or of elimination of systemic opioid use were captured.37 
 
[Insert Figure 1 here] 
 
Seven studies were included in the final set of relevant studies (Table 2). Six of the studies were 
published in peer-reviewed journals 38,39,41-44 and one was a conference proceeding.40 The study 
designs in the seven studies varied considerably. Two of the studies were retrospective analyses of 
database records 38,39 while another pair were retrospective case series.40,41 Two model-based 
studies were identified.42,43 Kumar et al. 43developed a Markov model based on retrospective 
assessment of patient notes and de Lissovoy et al. 42 a Markov model based on the literature. One of 
the studies was an economic evaluation based on an RCT.44 
In terms of the type of analysis, the two retrospective database studies were partial economic 
evaluations: one cost-analysis evaluation 38 and one cost description study.39 The other five studies 
were full economic evaluations including, two cost-consequence analyses;40,44 two cost-utility 
analyses;41,43 and one cost-effectiveness analysis.42 
 
[Insert Table 2 here] 
 
Findings from economic evaluations of ITDD 
The five full economic evaluations included in this systematic review found that ITDD is a cost-
effective alternative to CMM (Table 3). The two cost-consequence analyses observed better patient 
outcomes and reduced costs following ITDD. Bensemmane et al reported an average treatment cost 
reduction per patient year of 26% following ITDD and improvements in pain and disability.40 Kumar 
et al saw an average improvement in disability of 27% and a break-even point in comparison to 
CMM at 28-months post ITDD implantation.44 The model-based cost-effectiveness analysis by de 
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Lissovoy et al found that only in a worst-case scenario would ITDD become more costly than CMM.42 
The cost-utility analyses by Biggs et al and Kumar et al reported that ITDD was cost-effective when 
compared to CMM at a willingness-to-pay (WTP) threshold of £30,000 per quality adjusted life year 
(QALY) gained in the UK and $20,000 per QALY gained in Canada respectively.41,43 Biggs and 
colleagues also observed that there was a reduction in costs between the decision to implant a 
patient and the actual procedure, which could have an impact in the cost-effectiveness analysis.41 
Kumar et al estimated an 84% probability that ITDD was a cost-effective alternative to CMM at the 
Canadian WTP threshold and that these results were resistant to parameter uncertainty.43 
Discrepant findings were reported by the two partial economic evaluations included in this 
systematic review. Guillemette et al observed that non-cancer pain patients that receive an ITDD 
implant experienced a reduction in future medical costs when compared to CMM.38 Thrasher and 
Fisher reported that the post-implantation costs were higher than the costs prior to implantation.39 
The time horizon for this study was six years which includes three years prior to implantation and 
three years’ post-implantation. Other studies have found that ITDD breaks-even within three years 
following implantation.38,44 
 
[Insert Table 3 here] 
 
Currency and price year adjusted findings 
For the purposes of comparison across studies, the cost estimates were converted to pounds sterling 
(£) for the price year 2016 (Table 4). The most important change occurred in the Biggs et al study but 
giving more relevance to what the authors had observed, i.e. a reduction in healthcare resource use 
in the period between the decision to implant a patient and the actual procedure (latent period).41 
The inclusion in the study time horizon of this latent period would lead to ITDD being considered 
cost-ineffective at the UK’s WTP threshold of £30,000 per QALY gained. This period was found to 
have an average duration of 263 ± 176 days (range 3–489).41 The incremental cost effectiveness ratio 
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(ICER) without and with the inclusion of a latency period were £26,080/QALY gained and 
£29,030/QALY gained respectively.41 These values increased to £29,453 and £32,784 after currency 
and price year adjustment. No relevant alterations were observed for the remaining studies. 
 
[Insert Table 4 here] 
 
Methodological aspects 
Perspective 
Four of the studies adopted a health services perspective 40,41,43,44 and the three US studies, that of 
the insurer.38,39,42 Thrasher and Fisher mention societal costs throughout the study.39 However, only 
costs from medical and pharmacy claims were analysed from the perspective of health insurance. It 
is also clearly stated by the authors that only direct costs were included and indirect costs, such as 
lost time or lost productivity, were not considered. Throughout the title, abstract and text, the term 
‘societal’ was incorrectly used as only insurance claims were considered. 
 
Costs, currency and price year 
All the included studies reported the currency, which included Canadian dollars,43,44 US dollars,38,39,42 
UK pounds sterling 41 and Euros.40 With the exception of the Bensemmane study, all of the studies 
reported the price year used.40 
There was considerable variation amongst the included studies regarding the costs that were 
included in their analyses. Equipment and implantation costs were included in all of the full papers. 
It is not clear whether these costs were included by Bensemmane et al which appears to only have 
included pharmaceutical costs, number of visits and days of hospitalisation.40 Costs of intrathecal 
drugs were considered by all the included studies but it is unclear if all the studies accounted for the 
refill procedure, which incurs a higher cost than just the intrathecal drug(s). A limitation evident in 
most of the studies was the non-inclusion of additional treatments and systemic medications that 
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patients may still require even if using an ITDD system. The exceptions were the studies by Biggs et 
al and Guillemette et al.38,41 
Only one of the studies acknowledged the omission of costs that would be relevant to address the 
economic question as a limitation of the study. Biggs et al did not include costs due to general 
practitioners appointments and prescriptions related to the patients’ pain but argued that the 
inclusion of these costs would lead to an increase of the cost-effectiveness of ITDD.41 The rationale 
was that as patients gain access to pain clinicians, it would be likely that patients require fewer GP 
appointments for pain-related causes. 
 
Measures of benefits used in the economic analysis 
The measure of benefit was the QALY in two of the studies, derived from responses to the EQ-5D 
instrument.41,43 The CCA by Kumar et al 44 used disability as measured in the Oswestry Disability 
Index, while de Lissovoy et al 42 defined efficacy as good to excellent pain relief. Two studies 
collected effectiveness data but did not employ a measure of benefit.40,44 The studies by Guillemette 
et al 38 and Thrasher and Fisher 39 were partial economic evaluations where no assessment of 
benefits was undertaken. 
 
Time horizons and discount rates adopted 
Chronic pain is typically a life-long condition and this would be the ideal time horizon for an 
economic evaluation in this population.24 The longest time horizon reported was 10-years in the 
economic model developed by Kumar and colleagues.43 The effectiveness data and estimates of 
complications were sourced from patients’ notes. The authors considered a 10-year time horizon as 
meaningful because robust outcome data was unavailable, and technological and pharmacological 
advances would have occurred within this period. All of the studies included had a time horizon 
longer than one-year. Guidance on the conduct of economic evaluations prescribes that costs and 
outcomes estimated over one year should be discounted at an appropriate rate, and reported.24 
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However, four studies either did not use or did not report a discount rate.39-41,44 Thrasher and Fisher 
evaluated information from a longitudinal claims database over a 6-year period.39 For patients with 
pre and post-implantation data, 12-months information before and after implant were considered in 
the analysis while information on just the first 12-months were considered in patients for whom only 
post-implantation data were available. Given that the total information content for the former 
patient group was 24 months, cost and benefits should have been discounted. 
Kumar et al. 43 and de Lissovoy et al. 42 used an annual 5% discount rate. Kumar et al. 43 discounted 
both costs and benefits, but it is not clear if de Lissovoy et al. 42 applied the discount rate to the 
treatment outcomes and cost or only the costs. In their cost-analysis, Guillemette and colleagues 
only discounted costs at a 3% annual rate.38 
 
Assessment of uncertainty 
Two studies did not assess uncertainty.39,40 Different approaches were observed in the remaining 
studies. Biggs et al. used a nonparametric bootstrapping approach to analyse the data.41 Guillemette 
et al. carried out univariate sensitivity analysis to investigate the impact of changes in the ITDD 
battery life, the pre-implant experience period and the medical cost trend assumptions.38  Sensitivity 
analyses in the form of best and worst-case scenarios were undertaken in de Lissovoy et al. 42 and 
Kumar et al.44 Kumar and colleagues also investigated the impact that an increase in the cost of the 
pump, increase in the pump’s battery life and a reduction in the costs of complications associated 
with ITDD surgery would have in the results.44 The rationale for choosing these aspects and the 
reason for not investigating the impact on the results, for example of a reduction in the pump’s 
battery life (the potential consequence of a higher intrathecal dose), is not clear. Kumar et al. carried 
out deterministic and probabilistic sensitivity analyses to identify key areas of uncertainty and 
determine model drivers.43 
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Generalisability of the results 
Most studies attempted to address the generalisability of the observed results to other settings, 
either by carrying out assessments of uncertainty or by comparing the results with those from 
previous studies. The exceptions to this were the abstract by Bensemmane et al. 40 and the study by 
Thrasher and Fisher.39 There were no indications that the results in Thrasher and Fisher were 
generalisable to settings outside the US. The authors discussed other studies that evaluated the 
cost-effectiveness of ITDD, however, they did not conduct a full economic evaluation and the 
perspective used was incorrectly claimed as societal. Kumar et al. attempted to address the 
generalisability of the results to other settings by reporting the costs and quantities separately, by 
carrying out sensitivity analyses and comparing the results obtained to those observed in previous 
studies.44 The data that informed the Markov model in Kumar et al. was obtained from a single 
centre, and as acknowledged by the authors, the model represents the management of a typical 
patient with chronic non-cancer pain at that particular centre.43 The authors carried out sensitivity 
analyses that demonstrated the robustness of the results. Kumar and colleagues compared their 
results with those from previous studies and to the WTP threshold adopted in the US and UK.43 
 
Methodological quality and limitations 
The conference proceedings abstract by Bensemmane et al. 40 does not contain sufficient 
information to allow quality assessment. Based on the Evers checklist, the studies addressed most 
items (Appendix 2).25 Five of the six studies addressed more than half of the items on the checklist. 
None of the studies addressed item 19, which relates to the discussion of ethical and distributional 
issues. Some of the studies were partial economic evaluations; therefore, items on outcome 
measures would be answered negatively. Based on the Evers checklist, the study by Thrasher and 
Fisher 39 was considered to be of the lowest quality as only four questions were answered positively. 
According to the Evers checklist, the best quality study was Kumar et al.,43 which just failed to 
address ethical and distributional issues. 
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Two of the studies were model-based economic evaluations and were therefore also assessed using 
the Philips checklist (Appendix 3).26 The first model was developed in 1997,42 before the publication 
of any specific checklist for economic models. Twenty-five out of 57 questions in the Philips checklist 
were either unclear or not addressed in de Lissovoy’s et al. model,42 and 15 questions were not 
applicable; 11 of 15 questions were in the ‘Data’ section of the checklist. The second model by 
Kumar et al. 43 addressed 35 questions in the checklist and only eight were answered negatively. 
According to the Philips criteria, the paper by Kumar et al. 43 presented a better quality economic 
model of ITDD for chronic non-cancer pain. 
 
Additional methodological issues 
In the abstract by Bensemmane et al the data was collected retrospectively from the medical 
records of five patients implanted during 2006/2007.40 Although the authors stated that data from a 
period of three years after implantation was collected, the effectiveness results only covered the 
first 12 months and it is not clear if the remaining data collected was limited to this period as well. 
Although the authors did not use a measure of benefit in the economic evaluation, effectiveness 
outcomes included the visual analogue scale (VAS) and Oswestry disability index (ODI). 
One of the economic models intended to focus on chronic intractable pain attributed to failed back 
surgery syndrome (FBSS).42 However, the authors considered that the available data on the rate of 
occurrence of specific complications associated with ITDD was sparse and therefore also pooled data 
from ITDD studies on cancer pain. Patients with cancer pain usually require higher intrathecal doses, 
leading to a higher rate per day, which contributes to faster battery depletion and consequent 
replacement. It is not clear if the data provided by the manufacturer on pump failure rates and 
pump life (median = 48 months) refers only to those patients with FBSS or also includes other non-
malignant aetiologies and cancer pain. The adverse event rates were converted into an annual rate 
and assumed to remain constant over the 60-month time horizon. Although this approach is 
acceptable, the most common complications which are catheter related occur early; the estimates 
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used are likely not reflective of current practices due to improvement in technology and for some 
adverse events, alternative time to event rates may need to be considered. The longest average 
follow-up in the studies included was 27.8 months. Some complications and associated co-
morbidities may occur or may be identified at later stages such as granulomas,45-47 
hypogonadotrophic hypogonadism 48,49 or decrease in bone mineral density 50,51 and could have an 
impact on the results observed. 
The only conventional management included by de Lissovoy et al in the ITDD group was 
supplemental medication with a base case cost of $59.42 Although patients receiving CMM are more 
likely to require interventions, in the long term, it is possible that patients receiving ITDD will also 
require additional treatments (e.g. spinal fusion, facet injections) if their condition deteriorates. A 
large discrepancy in the cost of medication was used for the model, with CMM patients estimated to 
have an annual medication cost of $4847 compared with ITDD patients cost of $59 per month or 
$708 per year. Patients receiving CMM may also experience complications / side-effects which have 
not been accounted for. 
Efficacy data used in de Lissovoy et al 42 was based on data from two studies.52,53 Neither of these 
studies had a focus on patients with FBSS and the administration route in the Auld et al study was 
epidural rather than intrathecal. For CMM patients, it was assumed that these would only have 
inadequate pain relief and therefore efficacy of CMM was valued as zero (i.e. zero months of pain 
relief), presumably for base, best and worst-case scenarios. 
It should be noted that although the data from Kumar et al 44 was based on a RCT, besides stating 
that the two groups were matched for age, sex and number of prior operations, the authors did not 
present additional details to assess the quality of the RCT design including information on power 
calculation, methods of randomisation or loss to follow-up. The authors collected effectiveness data 
using the ODI, VAS and patient satisfaction. While the results for improvement in disability using the 
ODI were presented for each group, the VAS and satisfaction were only reported for those patients 
receiving ITDD, therefore not allowing comparisons with the CMM group. 
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Guillemette et al extracted data over a six-year period, which covered three years prior to implant, 
implant month and three years following implant.38 The data for this period of time was used as the 
basis for extrapolating the patient medical costs over a 30-year time horizon. The pre-implant data 
was used to simulate a CMM protocol to compare with the actual post-ITDD implant claim 
experience to determine the difference in outcomes. For the simulation of the CMM protocol, it was 
assumed that the patients costs would follow the patterns as experienced during the pre-implant 
period. Although the authors indicated that the data extracted were for a six-year period, from a 
sample size of 555, only 7% (n=39) of the patients prior to implant and 8.3% (n=46) of the patients 
post-implant provided three-year data for each of the time periods. However, when the authors 
present the three-year ‘actuarial’ cost projection for the CMM group post-implant, the number of 
patients is claimed to be 46, when in fact the information had been derived from the data of 39 
patients (those with prior to implant data). 
 
DISCUSSION 
This systematic review investigated the cost-effectiveness of ITDD for the management of chronic 
non-cancer pain. Although a limited number of economic evaluations were identified, six of the 
seven studies indicate that ITDD is a cost-effective alternative to CMM for this population. While 
differences across the studies in terms of type of economic evaluation, perspective adopted and 
setting in which ITDD was evaluated do not allow to draw firm conclusions, this systematic review 
reveals important points that are relevant for future economic evaluations of ITDD for chronic non-
cancer pain. An important finding of this review concerns the limitations and biases observed in 
current literature which should be taken into account in subsequent economic evaluations; mainly: 
 No RCT evidence on the effectiveness of ITDD for chronic non-cancer pain which could 
inform an economic evaluation; 
 CMM not standardised across the studies and unclear if standardised within studies; 
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 Systematic review of effectiveness and safety data not performed to inform development of 
existing economic models; 
 Costs may have been underestimated as not all costs related to interventions for the 
management of the patients’ pain were included in the studies; 
 Costs associated with complications due to CMM not included in the studies; 
 Discount rates were not used in all studies with a time horizon longer than one year; 
 No economic evaluations have been conducted adopting a societal perspective. 
 
Strengths and weaknesses of the current review 
This systematic review focused on the cost-effectiveness of ITDD for chronic non-cancer pain. 
Comprehensive methods were employed, including searches in key electronic bibliographic 
databases, citation searching and discussion with experts. The search results were also not restricted 
for language, type of study or type of economic evaluation. Furthermore, an assessment of the 
quality of all of the studies was performed including an additional quality assessment of model-
based economic studies where appropriate. Because there is currently no agreement as to a 
minimum methodological criterion to be applied to decide whether economic evaluations are 
included in systematic reviews, no study was excluded based on quality assessment. The implication 
is that the review explored the full range of costs and outcomes for ITDD. Although studies have 
investigated the impact of excluding studies following quality assessment on results of systematic 
reviews,28 there is currently no consensus on how to generate a score or the value of these scores 
from the Evers et al. 25 and Philips et al. 26 checklists. A study by Thurston et al. identified six different 
scoring systems,54 however, quality-scoring systems have several limitations, their use is not 
currently recommended and it is preferable to present a checklist or a descriptive critical 
assessment.55 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Pooled estimates of costs and cost-effectiveness were not produced in this systematic review. The 
value of meta-analytic methods remains unexplored, and the feasibility and usefulness of this 
technique for economic data requires further study.56 It has been argued that the genuine 
contribution that a systematic review of economic evaluations can provide is to help identify the 
most relevant studies considering the decision problem and setting; understanding the causal 
relationships in a decision problem or policy area; and informing decision model development.56-58 
Considering the decision problem (is ITDD a cost-effective alternative to CMM) and setting 
(hospital), the most relevant study identified was Kumar et al.43 Only one study was conducted in the 
UK, although it was based on a single-centre and with a small sample size.41 Both studies found ITDD 
to be a cost-effective alternative to CMM. The longest time horizon in the currently available 
literature is 10-years, but a model with a life-long time horizon would be the most beneficial. Other 
factors to contemplate when developing a model-based economic evaluation of ITDD include 
consideration of systemic medication and additional treatments (despite the use of an ITDD), 
complications that may occur following the prolonged use of ITDD, changes in practice and 
technology, complications following CMM, and societal costs. Societal costs are likely to assume 
particular importance considering the life-long nature of this condition, potential deterioration of 
the patient and continuous support necessary. It should be noted, that none of the studies identified 
included or discussed societal costs and its potential implications for the economic evaluation of 
ITDD. 
 
Limitations of included studies 
Limitations inherent to the studies included also contribute to the strengths and weaknesses of this 
review. The main limitation is the reduced number of available full economic evaluations. Five full 
economic evaluations were identified, one of which was merely published as a conference 
proceeding abstract. There were several methodological limitations in the studies included. Four of 
the studies did not mention the use of a discount rate, and none of the studies used a life-long time 
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horizon which would be appropriate for this chronic condition. Furthermore, five of the seven 
studies relied on cost and outcome data from either database claims data or retrospective 
assessment of patients notes. The data for one of the studies44 came from an RCT, however there 
are not many details to appraise the quality of the RCT, and the results of the RCT were not 
published in a separate paper. Therefore, a quality assessment for the effectiveness study on which 
this economic study was based was not performed. The data to inform the remaining study 42 was 
derived from a literature review, although due to the limited available literature, the authors had to 
extract data from cancer pain papers. Although the studies included were conducted in the UK, 
France, Canada and the US, and considered different perspectives, the majority of the studies 
concluded that ITDD was less costly or cost-effective when compared to CMM. Only one of the 
studies considered that the costs of ITDD are superior to CMM.39 However, this study was judged as 
the one with the lowest quality and the perspective was incorrectly presented; claimed to be 
societal when it was in fact that of the insurer. The findings from Thrasher and Fisher 39 may have 
occurred since there may be a reduction in health care costs once the patient is informed of 
suitability for ITDD. The reduction in health care costs at this stage may lead to a significant impact in 
the results of the economic assessment, although reliant on delay period between decision and 
implantation, which is practice dependent.41  
 
Implications for policymakers 
NHS England currently commissions the use of ITDD for the management of severe cancer pain 17 
and spasticity.18 However, NHS England does not routinely commission ITDD for severe chronic non-
cancer pain as it was considered that there was insufficient evidence to support routine 
commissioning.19 The economic studies used for the decision concerning ITDD for severe chronic 
non-cancer pain were de Lissovoy et al 42 [although Mueller-Schwefe et al. 32 was referenced], Kumar 
et al 44 and Bolash et al 29. It is important to note that Bolash et al. included patients with non-cancer 
pain, spasticity and cancer pain, but cost results were not presented separately for the different 
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aetiologies. This systematic review therefore assumes particular importance, and it is thought that 
its findings may be taken into consideration when this policy is reviewed in 2017. Nevertheless, the 
main limitation in the currently available literature is the absence of an RCT on ITDD in non-cancer 
pain patients. Despite this lack of RCT evidence, it is unlikely that such study would obtain funding 
and report its findings within this timeframe. RCT evidence is difficult to produce for a fourth or fifth 
line therapy due to lack of a plausible comparator therapy at this stage. Alternatively, long-term 
observational studies may provide appropriate data to inform a model-based economic study with a 
longer time horizon. A de novo economic evaluation should take into account the aspects identified 
through this review and addressing the limitations of previous economic evaluations. Similarly to 
other medical technologies, ITDD has high initial costs, but according to the identified economic 
evaluations, the cost of ITDD breaks-even within two to three-years following implantation when 
compared to CMM and has reduced costs subsequently. 
 
Future research 
A limitation of currently available literature in the field of ITDD for chronic non-cancer pain is the 
lack of robust effectiveness studies. Systematic reviews which investigated the clinical effectiveness 
of ITDD for the management of chronic non-cancer pain did not identify RCTs in this area.59-63 There 
has been a recently published RCT evaluating the efficacy of ITDD by randomising the patients to 
either a dose reduction group or a dose maintenance group.16 Although this study supports the 
efficacy of ITDD, the design is not adequate for use in an economic evaluation since the same 
intervention (ITDD) is being compared. The lack of reliable data limits the value and interpretation of 
economic evaluations in this field. An adequately powered RCT comparing ITDD to CMM with a 
nested economic evaluation is therefore necessary to address enduring uncertainties around the 
clinical effectiveness and the cost-effectiveness of ITDD for chronic non-cancer pain. 
Alternatively, a systematic review of effectiveness, safety and cost data to inform a de novo 
economic evaluation comparing ITDD to CMM could be carried out. An HTA of ITDD has been 
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previously conducted.59 This HTA did not develop an economic model and a plethora of additional 
evidence has been published since which could be valuable to inform such a model. Recently, an 
HTA from Health Quality Ontario identified four economic evaluations of ITDD for non-cancer pain, 
not considering partial economic evaluations.64 In the HTA, quality of the economic evaluations was 
assessed using the Phillips checklist which should only be used for model-based economic 
evaluations. The authors scored the quality of the economic papers (low and very low), although the 
Phillips checklist was not developed or validated for this purpose. The HTA considered that current 
evidence does not establish (or rule out) superiority or cost-effectiveness of ITDD for managing 
chronic non-cancer pain. We agree with the HTA report that evidence from within-trial studies is 
weak. However, models are meant to address this issue. The results suggest that model ICERS are 
only higher than the £20,000/QALY threshold in extremely conservative scenarios, therefore 
suggesting that in the absence of better evidence, ITDD should be funded by the NHS. The 
commissioning of SCS for the management of complex regional pain syndrome (CRPS) and FBSS in 
the UK followed the publication of the Simpson et al. HTA.65 The data to inform the SCS economic 
model was however based on RCT evidence. 
In relation to methodological research a survey observed that for decision makers that require 
information on the quality and relevance of health economic studies, it would be of most use to 
have a combination of a summary or score, together with a short abstract.54 Taking into 
consideration the above-mentioned difficulties to generate a single score based on quality 
assessment tools of economic evaluations; currently, the best alternative would be to present a 
checklist together with a short abstract. It may be beneficial, that such a format is requested by NHS 
England following a systematic review of the economic evidence to better inform the next policy 
review of ITDD for chronic non-cancer pain. 
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CONCLUSION 
This systematic review identified seven economic evaluations of ITDD for chronic non-cancer pain. 
Six of the seven studies concluded that ITDD was less costly or cost-effective compared to CMM for a 
chronic non-cancer pain population. Despite the homogeneity in these findings, the main limitation 
of the currently available evidence is the lack of robust effectiveness data to inform economic 
evaluations, which also limits the robustness of the results observed. In addition to summarising the 
existing literature on the cost-effectiveness of ITDD, this systematic review identified factors that 
need to be taken into consideration in the process of model development and discusses implications 
for policymakers. Of particular importance is the fact that the recent NHS England policy review of 
ITDD for severe chronic pain did not take into account the better quality economic evidence, relying 
instead on lower quality studies including one which included cancer pain and spasticity patients. In 
some occasions, it is possible that important evidence with potential to influence decisions may not 
have been identified. Therefore, if there is uncertainty about the clinical effectiveness or cost-
effectiveness of a treatment, a systematic review should be commissioned prior to a decision. The 
authors do not state that this review alone or the use of better quality economic evaluations would 
lead to a change in the decision, due to the limited evidence for effectiveness. However, economic 
models are meant to address the lack of effectiveness data. In the absence of better evidence, the 
results observed suggest that ITDD should be funded by the NHS based on the model ICERs 
observed. Even with better effectiveness data, the assessment of poor economic evaluations (when 
better evidence is available) could tip the decision towards non-commissioning and as a 
consequence, access to patients with non-cancer pain that could potentially benefit from ITDD 
would be denied. For the large majority of these patients, ITDD is the last option to obtain 
improvements in quality of life. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Figure legends 
Figure 1. PRISMA flow diagram detailing the literature search 
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Table 1. Inclusion criteria for identification of relevant studies 
Population Patients with chronic non-cancer pain lasting for at least three months prior to 
intervention 
Intervention  ITDD systems using opioids alone or in combination with other agents 
Comparator  Any comparator 
Outcomes  Effectiveness data (i.e. patient reported quality of life, pain intensity, 
disability, patient satisfaction) – only applicable for full economic evaluations 
 Direct and/or indirect costs to the health care system, patients and society 
 Items on resource use 
 Cost per unit of outcome (i.e. cost-per-QALY, incremental cost-effectiveness 
ratio) 
Study design   Full or partial economic evaluations as defined by Drummond et al.24 
Type of economic evaluation Comparison of 
two or more 
alternatives? 
Costs 
examined? 
Consequences 
examined? 
Full economic evaluation 
      Cost-minimisation analysis Yes Yes No* 
   Cost-consequence analysis Yes Yes Yes 
   Cost-effectiveness analysis Yes Yes Yes 
   Cost-benefit analysis Yes Yes Yes 
   Cost-utility analysis Yes Yes Yes 
    Partial economic evaluation 
      Cost analysis Yes Yes No 
   Cost description No Yes Yes 
   Cost-outcome description No Yes No 
* consequences assumed to be equal 
 
ITDD, intrathecal drug delivery; QALY, quality-adjusted life years; QoL, quality of life. 
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Table 2: Characteristics of the included studies 
Author & year Funding Country Setting 
Sample 
size Age Gender (%) Diagnosis Study design Interventions Effectiveness data Cost data 
Bensemmane 
2011 40 
None 
declared 
France Secondary 
care 
5 NR NR Chronic LBP Retrospective 
case series 
CMM with 
ITDD versus 
CMM alone 
Hospital visits and 
hospital days per 
patient per year, 
number of 
pharmaceuticals, ODI, 
VAS 
Costs of pharmaceuticals 
and ITDD. All costs were in 
Euros (€). Unclear if the 
price year was 2011. 
Biggs 2011 41 None 
declared 
UK Secondary 
care 
12 54 ± 11 y 
(SD) 
7 Female 
(58%) 
Chronic LBP Retrospective 
case series 
CMM with 
ITDD versus 
CMM alone 
EQ-5D Costs of surgery and 
injection treatments, 
investigations, drugs, and 
consultations for pain 
management. All costs 
were in pounds sterling (£), 
for the price year 2009. 
de Lissovoy 
1997 42 
Contract 
between 
Medtronic, 
Inc., and the 
Battelle 
Memorial 
Institute, 
Washington, 
DC 
US Secondary 
care 
1000 N/A N/A Neuropathic 
pain (FBSS) * 
Economic model 
based on review 
of the literature 
CMM with 
ITDD versus 
CMM alone 
Efficacy defined as 
good to excellent pain 
relief ranged from 65% 
(worst case) to 81% 
(best case). Base case 
was the average of the 
two figures (73%). Base 
case for duration of 
pain relief was 
calculated as 60 
months x 0.73. 
Assumed to be 0 for 
CMM group. 
Analysis of expenditures for 
alternative modalities and 
analysis of billing data for 
patients of two of the 
authors. Physician fees 
were adjusted upwards to 
the average private sector 
using a Medicare to private 
sector payment ratio of 
0.64. Costs were in US 
dollars ($) for the price year 
1994. 
Guillemette 
2013 38 
Funded by 
Medtronic, 
Inc. 
US Secondary 
care 
555 Median age 
group = 50 
to 59 
205 Female 
(37%) 
Chronic non-
cancer pain 
Retrospective 
database 
analysis of 
claims data 
CMM with 
ITDD versus 
CMM alone 
N/A Cost data was derived from 
a national claims database, 
comprising medical and 
prescription drug claims. 
Annual trend rates were 
applied to the 
reimbursement amounts 
based on each claim's date. 
An annual discount rate of 
3% was used. Costs were in 
US dollars ($) for the price 
year 2007. 
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Kumar 2002 44 None 
declared 
Canada Secondary 
care 
Total - 67 
ITDD 
group - 
23 
CMM 
group - 
44 
NR ITDD group - 
32 F (48%) 
CMM group - 
21 F (48%) 
FBSS RCT CMM with 
ITDD versus 
CMM alone 
ODI, VAS, patient 
satisfaction 
Cost references were taken 
from province's fee 
schedule where the study 
was conducted (Regina, 
Saskatchewan, Canada). 
Costs of the implantable 
devices were obtained 
from the manufacturer. 
The costs for each category 
were tabulated and 
averaged for a 5-year 
period. Costs were in 
Canadian dollars ($) for the 
price year 2000. 
Kumar 2013 43 None 
declared 
Canada Secondary 
care 
Total - 
169 
ITDD 
group - 
125 
CMM 
group - 
44 
ITDD group 
- 52 y 
CMM 
group - 51 
y 
ITDD group - 
58 F (46%) 
CMM group - 
21 F (48%) 
Chronic non-
cancer pain 
Economic model 
based on 
retrospective 
assessment of 
patient's notes 
CMM with 
ITDD versus 
CMM alone 
EQ-5D Cost references were taken 
from province's fee 
schedule where the study 
was conducted (Regina, 
Saskatchewan, Canada). 
Costs of the implantable 
devices were obtained 
from the manufacturer. 
Costs were in Canadian 
dollars ($) for the price year 
2011. 
Thrasher 2013 
39 
Funded by 
Pentec 
Health, Inc. 
US Secondary 
care 
Before 
and after 
implantat
ion - 
1139 
After 
implantat
ion only - 
22582 
Range: 18-
64 y 
NR Chronic pain Retrospective 
database 
analysis of 
claims data 
ITDD N/A Cost data were obtained 
from a claims database of 
14 commercial health plans 
operating throughout the 
US comprising medical and 
pharmcy claims. Costs were 
in US dollars ($) for the 
price year 2011. 
* Data from studies of ITDD on cancer pain was pooled for the rate of occurrence of specific complications 
CMM, conventional medical management; FBSS, failed back surgery syndrome; ITDD, intrathecal drug delivery systems; LBP, low back pain; N/A, not applicable; NR, not reported; ODI, Oswestry disability index; RCT, 
randomised controlled trial; VAS, visual analogue scale; y, years 
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Table 3. Findings from the included studies 
Author & year Type of economic 
evaluation 
Perspective Time 
horizon 
Measure of 
benefit 
Analysis of uncertainty Results Conclusions 
Bensemmane 
2011 40 
CCA Health service 8 years VAS Not performed Average treatment cost per patient per 
year decreased by 26% from €3,163 
(drugs) to €2,326 (€806 drugs + €7600 
pump cost amortised over 5 years). 
Average number of visits and hospital 
days per patient per year decreased by 
30% (from 10 to 7 consultations) and 
37% (6.2 days 3.9 days) respectively. 
The use of ITDDs appears to provide 
better management of pain and 
decreased treatment costs. However, 
this study covers only 5 patients over a 
short period and does not include the 
cost of installation and monitoring 
costs. A prospective study on a larger 
number of patients is needed to 
confirm these preliminary results. 
Biggs 2011 41 CUA Health service 4 years 
plus latent 
period 
QALY Results presented using 
nonparametric bootstrapping 
The estimated mean QALYs were 
0.3341 before implantation and 0.6458 
after implantation.  When including the 
latent period the incremental cost per 
QALY gained with the ITDD versus 
CMM was £29,029.52. When excluding 
the latent period the incremental cost 
per QALY gained with the ITDD versus 
CMM was £26,079.54. 
ITDD offers an economically feasible 
alternative solution for chronic non-
malignant pain patients whose current 
treatment is inappropriate or 
ineffective. Assessments of the cost 
effectiveness of a health care 
treatment should take into 
consideration the existence of a latent 
period since this may influence not only 
cost efficacy evaluations but also 
decisions to go through with a 
treatment. 
de Lissovoy 1997 
42 
CEA Third party 
(Medicare) 
5 years Efficacy 
defined as 
good to 
excellent 
pain relief 
Sensitivity analyses were 
conducted on all parameters of 
the model by varying their 
values across low (best case) to 
high (worst case) ranges to 
assess the effects on projected 
total cost. The best case value 
was set at 50% and the worst 
case value set at 200% of the 
base case. Elasticity values 
were calculated. 
The incremental cost per year of pain 
relief for the base case was -$624,  -
$7,832 for the best case and $12,276 
for the worst case. Based on the 
elasticity value, the cost of the 
pump/catheter implant, ongoing 
monthly expenses for therapy, and 
pump replacement were the most 
sensitive parameters of the model. 
ITDD appears to be cost-effective when 
compared with alternative (medical) 
management for selected patients 
when the duration of therapy exceeds 
12 to 22 months. 
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Guillemette 2013 
38 
Cost analysis Third party 
(private 
commercial 
and Medicaid) 
Data for a 
6-year 
period was 
modelled 
over 30-
years 
N/A Univariate sensitivity analysis: 
1) changes in the ITDD 
system’s battery life; 2) 
altering the preimplant 
experience period used to 
establish starting average cost 
for projection purposes; and 3) 
altering the medical cost trend 
assumptions. 
ITDD was found to break-even in 
comparison to CMM after 27 months 
post-implant. Analysis of the 30-years 
post-implant time horizon indicates 
annual per patient savings of $3,111 
compared with CMM. Sensitivity 
analyses indicated that an ITDD life 
expectancy increase of 50% would 
result in an increase of 311% in patient 
per year savings. If assuming a 3-year 
ITDD replacement cycle, ITDD would 
cost more than CMM over the 30-year 
time horizon. The other variables 
subjected to sensitivity analysis did not 
impact on the results. 
Non-cancer pain patients that receive 
an ITDD implant may experience 
reduced future medical costs relative to 
anticipated costs under conventional 
therapeutic methods. The level of 
savings is sensitive to the duration of 
the implantation cycle. The longer the 
cycle, the greater the savings as 
implantation costs are amortised over 
the cycle period and reductions in 
patient utilisation begin to accumulate. 
Implant financial break-even point is 
likely to occur soon after the second 
year for non-cancer pain patients. 
Kumar 2002 44 CCA Health service 5 years ODI Best and worst-case scenarios. 
Best-case group consisted of 9 
patients who experienced no 
complications in the 5-year 
follow-up period. Worst-case 
group consisted of 14 patients 
who experienced 1 or more 
complications during the 
follow-up period. Sensitivity 
analyses were conducted for 
cost of the pump, changes in 
the pump battery's life and 
complications associated with 
surgery for ITDD. 
The cumulative costs per patient 
receiving ITDD for a 5-year period 
equalled $29,410. The cumulative costs 
per patient receiving CMM totalled 
$38,000 during the 5-year period. The 
cumulative costs for patients receiving 
ITDD in a best and worst-case scenarios 
were $28,264 and $31,131 
respectively. ITDD was found to break-
even in comparison to CMM at 28 
months in the base-case scenario, 26 
months best-case scenario and 30 
months in the worst-case scenario. 
Sensitivity analyses indicated that an 
increase in the cost of the pump would 
lead to a delay in break-even point, an 
increase in the pump battery life would 
have no impact in the break-even 
point, while a decrease in costs 
associated with complications would 
shorten the break-even point to 26 
months. Patients receiving ITDD 
experienced an average improvement 
in disability of 27% over the 5-year 
period compared with 12% 
improvement in those patients in the 
CMM group. 
ITDD is a cost-effective method of 
treating chronic non-malignant pain 
caused by FBSS in patients who 
respond positively to an initial trial of 
ITDD. This holds true even when 
considering worst-case scenarios in 
which multiple complications may be 
involved. Additional benefits include 
increased ability to work and improved 
QoL with better pain control. Further 
cost savings will result from 
technological advances that will 
increase the life span of the pumps and 
improvements in catheter design that 
will decrease the incidence of their 
fracture, occlusion, and detachment. 
Better understanding of the long-term 
cost implications of ITDD compared 
with CPM will lead to more effective 
allocation of scarce health care 
resources. 
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Kumar 2013 43 CUA Health service 10 years QALY Deterministic and probabilistic 
sensitivity analyses were 
conducted. For the cost and 
efficacy parameters, the 
extremes of ±20% from the 
mean were selected as 
reasonable upper and lower 
bounds. 
The incremental effectiveness of ITDD 
was 1.1508 QALYs, at an incremental 
cost of $13,034, which produced an 
ICER of $11,326/QALY. Results from 
deterministic and probabilistic 
sensitivity analyses revealed that the 
cost effectiveness of ITDD was resistant 
to parameter uncertainty. The 
probability of ITDD providing a cost-
effective alternative to CMM at a WTP 
threshold of $20,000/QALY was 84%. 
Over 10 years, a patient in ITDD 
treatment will, on average, accrue an 
additional 1.15 QALYs compared with 
CMM. ITDD is a cost-effective 
treatment strategy compared with 
CMM, generating an ICER of 
$11,326/QALY, which falls below 
commonly accepted WTP thresholds. 
Significant cost savings can be attained 
with the use of ITDD in patients with 
chronic non-cancer pain. 
Thrasher 2013 39 Cost description Third party 
(medical and 
pharmacy 
claims) 
6 years N/A Not performed For those patients with data for before 
and after implantation, the costs of 
care pre-implant (mean ± SD) were 
$15,873 ± 25,273, the implantation 
costs were $24,413 ± 39,851 and post-
implant costs were $23,541 ± 77,546. 
For those patients with only post-
implantation data, the medical costs 
were $15,034 ± 63,950 and the 
pharmacy costs were $451 ± 2805.  
The societal costs for ITDD patients are 
high and extremely variable. This 
heterogeneous population is complex 
and represents a heavy societal cost 
burden. Our data highlight the open-
ended risk these patients represent for 
a health insurance plan and society as a 
whole. The opportunity exists to 
drastically change this pattern with a 
method to better identify the highest-
risk individuals and develop an 
improved care model that is able to 
minimise some of the cost variability. 
CCA, cost-consequence analysis; CMM, conventional medical management; CE, cost-effectiveness analysis; CUA, cost-utility analysis; ICER, incremental cost effectiveness ratio; ITDD, intrathecal drug delivery system; 
ODI, Oswestry disability index; QALY, quality-adjusted life-years; QoL, quality of life; VAS, visual analogue scale; WTP, willingness-to-pay 
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Table 4. Findings from the included studies (currency and price year adjusted) 
Author & year Findings Findings (currency and price year adjusted) * 
Bensemmane 2011 
40
 Average treatment cost per patient per year 
decreased from €3,163 (drugs) to €2,326 
(€806 drugs + €7,600 pump cost amortised 
over 5 years). 
Average treatment cost per patient per year 
decreased from £2,804 (drugs) to £2,062 
(£715 drugs + £6,738 pump cost amortised 
over 5 years) 
Biggs 2011 
41
 With latent period included, the incremental 
cost per QALY gained with the ITDD versus 
CMM was £29,029. When excluding the latent 
period the incremental cost per QALY gained 
with the ITDD versus CMM was £26,079. 
With latent period included, the incremental 
cost per QALY gained with the ITDD versus 
CMM was £32,784. When excluding the 
latent period the incremental cost per QALY 
gained with the ITDD versus CMM was 
£29,452. 
de Lissovoy 1997 
42
 The incremental cost per year of pain relief for 
the base case was -$624 -$7,832 for the best 
case and $12,276 for the worst case. 
The incremental cost per year of pain relief 
for the base case was -£654 -£8,213 for the 
best case and £12,873 for the worst case. 
Guillemette 2013 
38
 Analysis of the 30-years post-implant time 
horizon indicates annual per patient savings of 
$3,111. 
Analysis of the 30-years post-implant time 
horizon indicates annual per patient savings 
of £2,473. 
Kumar 2002 
44
 The cumulative costs per patient receiving 
ITDD for a 5-year period was $29,410 and 
$38,000 for patients receiving CMM over the 
same period. The cumulative costs for patients 
receiving ITDD in a best and worst-case 
scenarios were $28,264 and $31,131 
respectively. 
The cumulative costs per patient receiving 
ITDD for a 5-year period was £22,972 and 
£29,682 for patients on CMM over the same 
period. The cumulative costs for patients 
receiving ITDD in a best and worst-case 
scenarios were £22,077 and £24,316 
respectively. 
Kumar 2013 
43
 The incremental effectiveness of ITDD was 
1.1508 QALYs while the incremental cost was 
$13,034 when compared to CMM generating 
an ICER of $11,326/QALY. 
The incremental effectiveness of ITDD was 
1.1508 QALYs while the incremental cost was 
£7,869 when compared to CMM generating 
an ICER of £6,829/QALY. 
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Thrasher 2013 
39
 For those patients with data for before and 
after implantation, the costs of care pre-
implant (mean ± SD) were $15,873 ± 25,273, 
the implantation costs were $24,413 ± 39,851 
and post-implant costs were $23,541 ± 
77,546. For those patients with only post-
implantation data, the medical costs were 
$15,034 ± 63,950 and the pharmacy costs 
were $451 ± 2,805.  
For those patients with data for before and 
after implantation, the costs of care pre-
implant (mean ± SD) were £11,888 ± 18,928, 
the implantation costs were £18,284 ± 
28,846 and post-implant costs were £17,631 
± 58,077. For those patients with only post-
implantation data, the medical costs were 
£11,260 ± 47,895 and the pharmacy costs 
were £338 ± 2,101.  
* Cost estimates were converted to pounds sterling (£) for the price year 2016 
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